GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Volatility

BioXcel Therapeutics (BioXcel Therapeutics) Volatility : 120.32% (As of May. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-15), BioXcel Therapeutics's Volatility is 120.32%.


Competitive Comparison of BioXcel Therapeutics's Volatility

For the Biotechnology subindustry, BioXcel Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Volatility falls into.



BioXcel Therapeutics  (NAS:BTAI) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioXcel Therapeutics  (NAS:BTAI) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


BioXcel Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics (BioXcel Therapeutics) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
Vimal Mehta director, officer: CEO, President, Secretary 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Richard I Steinhart officer: Chief Financial Officer 125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez officer: SEE REMARKS C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Krishnan Nandabalan director, 10 percent owner 228 VILLAGE POND ROAD, GUILFORD CT 06437
Akrati Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello 10 percent owner 10 TEMPLETON ROAD, WALLINGFORD CT 06492
Krunal Dilip Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Alka Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Pardeep Kumar Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Anita Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437

BioXcel Therapeutics (BioXcel Therapeutics) Headlines

From GuruFocus